BCV Raises €6M Series A
Retrieved on:
Wednesday, December 13, 2023
Research, General Health, Professional Services, Medical Devices, Technology, Other Professional Services, Clinical Trials, Science, Biotechnology, Finance, Other Technology, Health, Peripheral artery disease, Safety, FAHA, NTI, Multimedia, Partner, FDA, FACS, CE, Stroke, Miniaturization, Lead, MD, Doctor of Philosophy, Gesture, BCV, Reims
This Series A funding brings the total amount raised since inception to €13M.
Key Points:
- This Series A funding brings the total amount raised since inception to €13M.
- “Our technology, applied to a guidewire, will be a disruptive change in minimally invasive procedures improving patients’ outcomes,” says Raphaël Blanc, M.D., Chairman & Co-Founder, BCV.
- “This round of financing will enable BCV to progress toward FDA and CE mark approval,” adds Thierry Col, CEO, BCV.
- The BCV system’s shape-memory alloy technology enables distal tip control improving practitioners’ gestures and demonstrating superior performance over existing advanced actuation technologies.